A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis

• Status: Completed
• Trial end date: 2003-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Must be 18 years of age or older at time of enrollment

• may be male or female

• Have had a diagnosis of plaque-type psoriasis at least 6 months prior to screening

• Have plaque-type psoriasis covering at least 10% of total BSA at baseline

• Have previously received PUVA and/or other systemic treatment for psoriasis

Exclusion Criteria:

• Have non-plaque forms of psoriasis

• Have a history of drug-induced psoriasis

• Are pregnant, nursing, or planning pregnancy within 12 months of enrollment

• Have had any previous treatment with infliximab or any therapeutic agent